ESTRO 2022 - Abstract Book

S154

Abstract book

ESTRO 2022

Conclusion We found TLI is a safe and effective procedure in stabilizing FEV 1 -decline in both BOS and RAS phenotypes, which should be considered early after CLAD diagnosis.

Symposium: Presidential Symposium: Learning from every patient

SP-0177 Introduction

B. Slotman 1

1 AmsterdamUMC, Radiation Oncology, Amsterdam, The Netherlands

Abstract Text The presidential symposium will focus on the theme of the meeting: “Learning from every patient”. Three excellent speakers will address various topics around this theme with emphasis on

• Innovative approaches to overcome barriers to clinical trial accrual

• Learning from individual patients

• Learning from large patient cohorts

SP-0178 Clinical trials: Innovative approaches to overcome barriers

D. Palma

Canada Abstract not available

SP-0179 Learning from patients

J. Haviland 1

1 The Institute of Cancer Research, Clinical Trials and Statistics Unit, Sutton, United Kingdom

Abstract Text The following aspects of learning from patients will be discussed: (i) the importance and use of patient-reported outcomes in research and clinical care, (ii) patient and public involvement in clinical research throughout the lifecycle of a study from design and conduct to interpretation and dissemination, and (iii) maximising use of data collected within routine care and clinical trials to inform future research and ensure that future patients benefit from knowledge gained.

SP-0180 Learning from large patient cohorts

B. Offersen 1

1 Aarhus University Hospital, Department of Experimental Clinical Oncology, Aarhus, Denmark

Abstract Text Evidence from large patient cohorts has the potential to provide further support of new therapies developed in randomised trials, but also demonstrate gains and risks from radiation therapy (RT) which may not be reported from other trials and studies. In particular, relatively seldom events may be documented only in large patient cohorts. The Danish Breast Cancer Group (DBCG) was established in 1977 to provide nationwide clinical guidelines for therapy of early breast cancer patients, and also develop new guidelines through evidence generating clinical studies. Denmark has 5.5 mio inhabitants, and currently around 4700 newly diagnosed breast cancer patients yearly. All Danish departments treating breast cancer patients report data on diagnosis, pathology, surgery, systemic therapy, RT and cancer events to the database. Every department follows the DBCG guidelines ensuring a homogeneous treatment strategy across the country. This strategy holds great potential for practice-changing clinical studies, and four examples are demonstrated here. The first example is the prospective cohort DBCG IMN (internal mammary node) study, where the DBCG RT Committee in 2003 decided not to irradiate the IMN in left-sided node-positive breast cancer patients, whilst IMN would be irradiated in right-sided breast cancer (1). The first results from >3.000 patients treated 2003-2007 according to this guideline were shown in 2014, whereafter the DBCG RT Committee immediately and unanimously modified the DBCG guidelines in favor of IMN RT for all node-positive breast cancer patients. The DBCG is currently investigating the cohort treated 2008-2014 according to the ±IMN guideline (N>5000 patients).